Rationale and Design of a Phase 3 Open-label Extension Study of Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea

Authors: P.J. Strollo, S.R. Patel, S.D. Pittman, K. Mehta, A. Azarbarzin, J. Cronin, L. Taranto-Montemurro, R. Farkas

Published: 2025-05-11

DOI: 10.1164/ajrccm.2025.211.abstracts.a6934

Source: Full article


Abstract

No abstract found.